Med en försäljningstillväxt på 9% under 2021/22 (Maj-April) ligger fokus på Qlucore nu på CE-märkningen av Diagnosticsplattformen under 2023. Därefter väntas en skarp ökning i intäkter mot det aggressiva målet på 300 MSEK till 2026. Se Emergers intervju med vd Carl-Johan Ivarsson här.
READ EMERGERS’ EQUITY RESEARCH ON QLUCORE HERE
QLUCORE | Expanding pipeline of precision diagnostics projects
With sales consisting of the data analytics software Omics Explorer, Qlucore reported revenue growth of 9% for the full year 2021/22 (May-April), while continued investments in the development of Diagnostics and Insights increased costs, in line with the company’s plan. In addition to the ongoing projects to develop classifier models for individualised treatment of three cancer indications, the new collaboration with Lund University to develop a solution for improved clinical diagnostics of bladder cancer, provide further support to both the company’s long-term revenue target over 300 MSEK in 2026E, and our combined DCF and multiple valuation with a fair value of SEK 53-75 per share in 12-24 months.
Magnus Brolin & Johan Widmark | 2022-05-31 12:00
This commissioned research report is for informational purposes only and is to be considered marketing communication. This research report has not been prepared in accordance with legal requirements designed to promote the independence of investment research and Emergers is not subject to any prohibition on dealing ahead of the dissemination of investment research. This research does not constitute investment advice and is not a solicitation to buy shares. For more information, please refer to disclaimer.
DISCLAIMER
